[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-514591-105":59,"doc-detail-514591-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","oncology-sera-and-soluble-tumor-markers-proficiency-testing-due-may-25-2011-instructions-for-laboratory-director","ONCOLOGY-SERA AND SOLUBLE TUMOR MARKERS PROFICIENCY TESTING DUE May 25, 2011 - Instructions for Laboratory Director","","Laboratory Director receives formal instructions for the Clinical Laboratory Evaluation Program proficiency testing for oncology serum and soluble tumor markers due May 25, 2011. Five sealed serum-based samples (TM226–TM230) must be analyzed for AFP, CEA, CA125, CA15-3, CA27.29, CA19-9, and PSA in all measured forms (total, free, and PSA-ACT when applicable). Results must be submitted electronically via EPTRS on the Health Commerce System before 11:59 PM, with attention to correct form completion and missing data rules.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/oncology-sera-and-soluble-tumor-markers-proficiency-testing-due-may-25-2011-instructions-for-laboratory-director/514591/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/oncology-sera-and-soluble-tumor-markers-proficiency-testing-due-may-25-2011-instructions-for-laboratory-director/514591.png","ImageObject",300,407,{"name":92,"@type":93},"hdkawk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-10-06",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"哪些肿瘤标志物需要在 TM226 到 TM230 样本中进行检测？","Question",{"text":112,"@type":113},"需对 AFP、CEA、CA125、CA15-3、CA27.29、CA19-9 以及 PSA 进行检测。若实验室常规检测自由 PSA/复合 PSA，还必须对所有样本测定对应的 PSA 形式。","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"样本应如何保存和使用？",{"text":117,"@type":113},"样本采用人源血清基质、经无菌过滤并分装。使用前确保样本完全混匀；保持冷藏直至使用，但不要冷冻，并按通用防护原则操作。",{"name":119,"@type":110,"acceptedAnswer":120},"如何以及何时提交熟练度测试（proficiency testing）结果？",{"text":121,"@type":113},"必须在 2011 年 5 月 25 日 11:59 PM 之前通过 EPTRS（位于 Health Commerce System 的安全网站）电子提交所有五个样本、所有常规测定分析物的结果。逾期未提交将按缺失处理并导致不合格评分。","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},514591,1792194759,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","***************PLEASE NOTE*************** This document and the worksheet can now be found on our website at:  \n[http://www.wadsworth.org/labcert/clep/PT/oncology/serasoluble/index.htm](http://www.wadsworth.org/labcert/clep/PT/oncology/serasoluble/index.htm)  \nTO: Laboratory Director  \nFROM: Erasmus Schneider, Ph.D.  \nDirector, Diagnostic Oncology Section, Clinical Laboratory Evaluation Program DATE: May 10, 2011  \nSUBJECT:  ONCOLOGY-SERA AND SOLUBLE TUMOR MARKERS PROFICIENCY TESTING DUE DATE: May 25th, 2011  \nPLEASE READ-INFORMATION IS IMPORTANT  \nSamples:  \nThere are five sealed (5) vials labeled TM226 to TM230, each containing diagnostic specimens for proficiency testing. Each vial contains various predetermined amounts of alpha-feto protein (AFP), carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), the breast cancer markers CA15-3 and CA27.29, the pancreatic cancer marker CA19-9 and prostate specific antigen (PSA) in all three currently measured forms, [i.e.](i.e. total)[ total](i.e. total) PSA, free PSA and complexed PSA (PSA-ACT) . Please analyze for all of those markers tested in your laboratory the same way as you would with a patient sample. If your lab is also measuring free and/or complexed PSA in addition to total PSA, you are also required to measure those forms of PSA in ALL of the samples provided. All materials used to prepare the enclosed samples were tested and found to be negative for HBV, HCV and HIV. Because no test can guarantee a sample to be non-infectious, it is recommended that universal precautions be used for handling samples. Samples are in a human-derived serum base, sterile filtered and dispensed. Please keep refrigerated until use, but do not freeze. Before analyzing make sure samples are completely mixed.  \nReporting of results: Results must be submitted electronically before 11:59 PM of May 25th, 2011. Please submit a little earlier if possible to allow time to resolve any problem you might have with result submission. Please also read the enclosed bulletin with important updates regarding the electronic proficiency testing reporting system.  \nAll laboratories must submit their proficiency testing results over the internet through the electronic proficiency testing reporting system (EPTRS) on the Department's Health Commerce System (HCS) . The HCS is a secure website and requires all users to obtain an ID in order to access the HCS and EPTRS application. Questions regarding the entry and submission of proficiency test results or the account application process can be directed to[clepeptrs@health.state.ny.us](clepeptrs@health.state.ny.us).  \nResults not submitted by the due date will be categorized as missing with an administrative failure and will receive a failing grade, even if the results were entered and saved but not officially submitted. Extensions are granted for exceptional reasons only, and you must contact the PT section as soon as possible before the due date to see if this can be arranged.  \nResults must be reported for all five samples for all analytes you routinely measure, otherwise a zero grade will be given to the missing data. Please enter your results in the spaces provided on the electronic PT form. If a result exceeds your analytical range, indicate this with a \"less than (\u003C)\" or \"greater than (>)\" sign if similar results from patient samples are reported in the same manner. If such samples are routinely retested after dilution, you may do so provided that the result is identified accordingly. Select the instrument and reagent/kit used for each analyte using the drop-down menus provided. Please check that the information is current, since the EPTRS form is pre-populated from previous entries. It is very important to correctly complete all applicable fields as missing or incorrect entries may result in an inability to move to the next screen, or possibly in test failure. If your lab has temporarily or permanently stopped testing for an analyte choose the appropriate","cbCaiiSyzX6z4Fj2","https://ap.wps.com/l/cbCaiiSyzX6z4Fj2","pdf",537334,21,"English","# Samples and analytes\n## Required markers (TM226–TM230)\n## Sample handling and safety\n# Result reporting requirements\n## Electronic submission and deadlines\n## EPTRS/HCS access and support\n## Scoring rules for missing or late results\n# Data entry and PSA-specific notes\n## Range handling and analyte status\n## Reference range cut-off interpretation\n## Free PSA and % free PSA guidance","[{\"question\":\"哪些肿瘤标志物需要在 TM226 到 TM230 样本中进行检测？\",\"answer\":\"需对 AFP、CEA、CA125、CA15-3、CA27.29、CA19-9 以及 PSA 进行检测。若实验室常规检测自由 PSA/复合 PSA，还必须对所有样本测定对应的 PSA 形式。\"},{\"question\":\"样本应如何保存和使用？\",\"answer\":\"样本采用人源血清基质、经无菌过滤并分装。使用前确保样本完全混匀；保持冷藏直至使用，但不要冷冻，并按通用防护原则操作。\"},{\"question\":\"如何以及何时提交熟练度测试（proficiency testing）结果？\",\"answer\":\"必须在 2011 年 5 月 25 日 11:59 PM 之前通过 EPTRS（位于 Health Commerce System 的安全网站）电子提交所有五个样本、所有常规测定分析物的结果。逾期未提交将按缺失处理并导致不合格评分。\"}]","ONCOLOGY-SERA AND SOLUBLE TUMOR MARKERS PROFICIENCY TESTING DUE May 25, 2011 - Instructions for Laboratory Director | PDF",1791300591,53]